Showing results (571-580 of 782) with videos related to
Sort By:
Pageof 79
European Journal of Haematology|February 4, 2012
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomibPaul G Richardson, Jacob P Laubach, Robert L Schlossman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2020
Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome GroupMehmet Kemal Samur, Anil Aktas Samur, Mariateresa Fulciniti, et al.American Journal of Hematology|July 24, 2010
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström MacroglobulinemiaIrene M Ghobrial, Wanling Xie, Swaminathan Padmanabhan, et al.Blood|January 14, 2017
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myelomaTeru Hideshima, Francesca Cottini, Yoshihisa Nozawa, et al.Cancer Cell|March 31, 2004
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumorsConstantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2025
Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple MyelomaAnil Aktas Samur, Jill Corre, Srikanth Talluri, et al.British Journal of Haematology|June 6, 2003
Viral antigen-specific CD8+ T-cell responses are impaired in multiple myelomaBritta Maecker, Karen S Anderson, Michael S von Bergwelt-Baildon, et al.British Journal of Haematology|June 29, 2006
In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cellsPaola Neri, Hiroshi Yasui, Teru Hideshima, et al.Nature Medicine|March 16, 2010
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activityDouglas W McMillin, Jake Delmore, Ellen Weisberg, et al.British Journal of Haematology|August 5, 2008
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myelomaRuben Niesvizky, Paul G Richardson, S Vincent Rajkumar, et al.Pageof 79